Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-cash Items: 2019-2025

Historic Non-cash Items for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $6.0 million.

  • 4D Molecular Therapeutics' Non-cash Items rose 45.40% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 45.40%. This contributed to the annual value of $54.5 million for FY2024, which is 16.30% up from last year.
  • 4D Molecular Therapeutics' Non-cash Items amounted to $6.0 million in Q3 2025, which was up 9.50% from $5.5 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Non-cash Items high stood at $54.5 million for Q4 2024, and its period low was $1.4 million during Q2 2021.
  • Its 3-year average for Non-cash Items is $12.5 million, with a median of $4.1 million in 2024.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Non-cash Items crashed by 74.60% in 2021, and later surged by 94.80% in 2022.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Non-cash Items stood at $24.7 million in 2021, then surged by 94.80% to $48.0 million in 2022, then declined by 2.47% to $46.9 million in 2023, then increased by 16.30% to $54.5 million in 2024, then skyrocketed by 45.40% to $6.0 million in 2025.
  • Its Non-cash Items stands at $6.0 million for Q3 2025, versus $5.5 million for Q2 2025 and $5.0 million for Q1 2025.